|本期目录/Table of Contents|

[1]田玉球,王冰清,袁 婷,等.髓源性抑制细胞在长期抗HBV 治疗患者中促进HBsAg 阴转的作用和机制探讨[J].传染病信息,2019,05:402-406.
 TIAN Yu-qiu,WANG Bing-qing,YUAN Ting*,et al.Role and mechanism of myeloid-derived suppressor cells inpromoting HBsAg seroclearance in patients after long-term anti-HBV treatment[J].Infectious Disease Information,2019,05:402-406.
点击复制

髓源性抑制细胞在长期抗HBV 治疗患者中促进HBsAg 阴转的作用和机制探讨(PDF)

《传染病信息》[ISSN:1007-8134/CN:11-3886/R]

期数:
2019年05期
页码:
402-406
栏目:
论著
出版日期:
2019-11-13

文章信息/Info

Title:
Role and mechanism of myeloid-derived suppressor cells inpromoting HBsAg seroclearance in patients after long-term anti-HBV treatment
文章编号:
1007-8134(2019)05-0402-05
作者:
田玉球王冰清袁 婷肖新强李 伟蒋永芳
412000,中南大学湘雅医学院附属株洲医院感染内科(田玉球、袁婷);410000长沙,中南大学湘雅二医院感染内 科(蒋永芳、李伟、王冰清、肖新强) 前两位作者对本文有同等贡献,均为第一作者
Author(s):
TIAN Yu-qiu WANG Bing-qing YUAN Ting* XIAO Xin-qiang LI Wei JIANG Yong-fang*
Department of Infectious Disease, The Affiliated Zhuzhou Hospital of Xiangya School of Medicine, Central South University, 412000,China Department of Infectious Disease, The Second Xiangya Hospital of Central South University, Changsha 410000, ChinaTIAN Yu-qiu and WANG Bing-qing are the first authors who contribute equally to the article
关键词:
慢性乙型肝炎乙型肝炎病毒表面抗原髓源性抑制细胞P47 phox
Keywords:
chronic hepatitis B HBsAg MDSCs P47phox
分类号:
R512.625
DOI:
10.3969/j.issn.1007-8134.2019.05.005
文献标识码:
A
摘要:
目的研究髓源性抑制细胞( myeloid-derived suppressor cells, MDSCs)、CD4+ T细胞、 CD8+ T细胞、 P47phox在抗病毒治疗后获得 HBsAg清除及未获得 HBsAg清除的 2种人群外周血中的频率和表达情况,探讨 MDSCs在肝炎慢性化及 HBsAg清除中的作用及机制。方法筛选 2007年 7月—2008年 7月慢性乙型肝炎( chronic hepatitis B, CHB)患者 80例予以抗 HBV药物 [恩替卡韦(博路定) ]治疗。采用流式细胞术检测治疗前 CHB组中 12例及 14例健康对照者外周血 MDSCs、CD4+ T细胞、CD8+ T细胞占外周血单个核细胞(peripheral blood mononuclear cells, PBMCs)总数的比例(即 MDSCs、CD4+ T细胞、 CD8+ T细胞频率)。追踪 CHB组患者,排除治疗过程中死亡、失访等患者,72例患者成功随访 8年。检测抗病毒治疗 8年后 8例 HBsAg转阴 [ HBsAg(-)组]与 64例未转阴 [ HBsAg(+)组 ]患者 PBMCs中 MDSCs、CD4+ T细胞、 CD8+ T细胞频率,用 Western blot技术检测 P47phox蛋白的表达。结果治疗前 CHB患者 PBMCs中 MDSCs频率显著高于健康对照者( P< 0.05),而 PBMCs中 CD4+ T细胞、 CD8+ T细胞频率与健康对照者无显著差异( P均> 0.05)。抗病毒治疗后 CHB患者中 HBsAg(-)组 PBMCs中 MDSCs频率低于 HBsAg(+)组, CD4+ T细胞及 CD8+ T细胞频率显著高于 HBsAg(+)组(P均< 0.05)。抗病毒治疗后 HBsAg(+)组外周血中 P47phox蛋白表达显著高于 HBsAg(-)组( P< 0.05)。结论CHB患者对 T细胞耐受可能与 MDSCs抑制 T细胞应答有关。 MDSCs可能通过活性氧途径发挥免疫抑制功能,减少 HBsAg清除。
Abstract:
ObjectiveTo study the frequency and expression of myeloid-derived suppressor cells (MDSCs), CD4+ T cells, CD8+ T cells and P47phox in peripheral blood of patients who obtained HBsAg seroclearance and failed to obtain HBsAgseroclearance after antiviral treatment, and investigate the role and mechanism of MDSCs in chronic hepatitis B and HBsAgclearance. MethodsEighty patients with chronic hepatitis B (CHB) were screened for receiving the treatment of anti-HBVagents [entecavir (baraclude)] from July 2007 to July 2008. The ratio of MDSCs, CD4+ T cells and CD8+ T cells in peripheralblood mononuclear cells (PBMCs) of 12 CHB patients before treatment and 14 healthy control subjects was measured by flowcytometry, as the frequency of MDSCs, CD4+ T cells and CD8+ T cells. The patients in the CHB group were traced and 72 patientswere followed up for 8 years after the death and lost cases during treatment were excluded. The frequency of MDSCs, CD4+ T cells and CD8+ T cells in PBMCs of 8 patients with HBsAg seroclearance [HBsAg(-) group] and 64 patients without HBsAgseroclearance [HBsAg(+) group] after 8-year antiviral treatment was measured. Western blot testing was employed to detectP47phox protein expression. ResultsThe frequency of MDSCs in PBMCs of CHB patients before treatment was significantlyhigher than that of healthy control subjects (P< 0.05). There was no significant difference in the frequency of CD4+ T cells and CD8+ T cells in PBMCs between CHB patients before treatment and healthy control subjects (P> 0.05). The frequency of MDSCsin PBMCs of HBsAg(-) patients with CHB was lower than that of HBsAg(+) patients after antiviral treatment, while the frequency of CD4+ T cells and CD8+ T cells in PBMCs of HBsAg(-) patients with CHB was significantly higher than that of HBsAg(+) patients (P< 0.05). The expression of P47phox protein in peripheral blood of HBsAg(+) group was significantly higher than that of HBsAg(-) group after antiviral treatment (P< 0.05). ConclusionsT cell tolerance in CHB patients may be associated with the inhibition of T cell responses by MDSCs. MDSCs may play an immunosuppressive role through the ROS pathway and reduce HBsAg clearance.

参考文献/References

[1] Chu CM, Liaw YF, CHE Y, et al. Hepatitis B surface antigenseroclearance during chronic HBV infection[J]. Antivir Ther, 2010, 15(2):133-143.
[2] Chen CJ, Yang HI. Natura history of chronic hepatitis B revealed[J]. J Gastroenterol Hepatol, 2011, 26(4):628-638.
[3] Betsch A, Rutgeerts O, Fevery S, et al. Myeloid-derived suppressorcells in lymphoma: the good, the bad and the ugly[J]. Blood Rev, 2018, 32(6):490-498.
[4] Talmadge JE, Gabrilovich DI. History of myeloid-derivedsuppressor cells[J]. Nat Rev Cancer, 2013, 13(10):739-752.
[5] Poschke I, Mougiakakos D, Hansson J, et al. Immature immunosuppressive CD14+HLA-DR-/low cells in melanomapatients are Stat3hi and overexpress CD80, CD83, and DC-sign[J]. Cancer Res, 2010, 70(11):4335-4345.
[6] Tacke R, Lee HC, Goh C, et al. Myeloid suppressor cells inducedby hepatitis C virus suppress T cell responses through the
production of reactive oxygen species[J]. Hepatology, 2012, 55(2):343-353.
[7] Yuan H, Cai P, Li Q, et al. Axitinib augments antitumor activity in renal cell carcinoma via STAT3-dependent reversal of myeloid?derived suppressor cell accumulation[J]. Biomed Pharmacother, 2014, 68(6):751-756.
[8] Wang, F, Jing X, Li G, et al. Foxp3+ regulatory T cells areassociated with the natural history of chronic hepatitis B and poorprognosis of hepatocellular carcinoma[J]. Liver Int, 2012, 32(4):644–655.
[9] Lu LR, Liu J, Xu Z, et al. Expression and clinical significance ofmyeloid derived suppressor cells in chronic hepatitis B patients[J]. Asian Pac J Cancer Prev, 2014, 15 (10):4367-4372.
[10] 中华医学会肝病学分会,中华医学会感染病学分会 .慢性乙型肝炎防治指南[J]. 中华肝脏病杂志,2005,13(12):881?891.
[11] Fang Z, Li J, Yu XY, et al. Polarization of monocytic myeloid?derived suppressor cells by hepatitis B surface antigen is mediated via ERK/IL-6/STAT3 signaling feedback and restrains theactivation of T cells in chronic hepatitis B virus infection[J].J Immunol, 2015, 195(10):4873-4883.
[12] Kim GA, Lee HC, Kim MJ, et al. Incidence of hepatocellularcarcinoma after HBsAg seroclearance in chronic hepatitisB patients: a need for surveillance[J]. J Hepatol, 2015, 62(5):1092-1099.
[13] Choong MU, Ton SH, Cheong SK. The cellular imumune statusof HBsAg postive carries in Malaysia[J]. Asian Pac J Allergy Immuno, 2011, 14(1):19-24.
[14] Lok AS, McMahon BJ. Chronic hepatitis B: update 2009[J]. Hepatology, 2009, 50(3):661-662.
[15] 梁敏锋 . 隐匿性 HBV感染和抗病毒治疗 HBsAg清除者的细胞免疫应答特点的研究[D].南京:南京医科大学,2007.
[16] 孟存仁,杨立,王家路,等 . 细胞免疫功能对乙型肝炎病毒复制及抗病毒治疗的意义[J].中国全科医学,2010, 13(7B):2226-2230.
[17] 李雪芬 . 慢性乙型肝炎患者 T淋巴细胞应答与抗病毒治疗疗效的相关性[C].中华医学会第九次全国检验医学学术会议暨中国医院协会临床检验管理专业委员会第六届全国临床检验实验室管理学术会议论文汇编 . 2011:北京 .
[18] 赵晓春,郭熙清,刘书宏,等 . 慢性乙型病毒性肝炎患者抗病毒治疗中细胞免疫功能的改变[J]. 安徽医药,2015, 19(1):108-110.

备注/Memo

备注/Memo:
[基金项目]“十三五”国家科技重大专项(2017ZX10202203-0080-006)
[作者单位]412000,中南大学湘雅医学院附属株洲医院感染内科(田玉球、袁婷);410000长沙,中南大学湘雅二医院感染内 科(蒋永芳、李伟、王冰清、肖新强) 前两位作者对本文有同等贡献,均为第一作者
[通信作者]袁婷,E-mail:1271915949@qq.com;蒋永芳,E-mail:Jiangyongfang@hotmail.com
*Correspondingauthor.YUANTing,E-mail:1271915949@qq.com;JIANGYong-fang,E-mail:Jiangyongfang@hotmail.com
更新日期/Last Update: 2019-11-13